A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
Phase 2
Not yet recruiting
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Target Recruit Count
- 134
- Registration Number
- NCT07034508
- Locations
- 🇨🇳
China Institute of Hematology and Blood Diseases Hospital, Tianjin, China
National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia
Recruiting
- Conditions
- T-LGL LeukemiaNK-LGL Leukemia
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-17
- Target Recruit Count
- 9999
- Registration Number
- NCT07019766
- Locations
- 🇨🇳
Red Blood Cell Diseases Center and Regenerative Medicine Center, Tianjin, Tianjin, China
National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia
Recruiting
- Conditions
- AIHA - Warm Autoimmune Hemolytic AnemiaAIHA - Cold Autoimmune Hemolytic AnemiaAutoimmune Hemolytic Anemia Mixed Type
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-17
- Target Recruit Count
- 9999
- Registration Number
- NCT07019038
- Locations
- 🇨🇳
Red Blood Cell Diseases Center and Regenerative Medicine Center, Tianjin, Tianjin, China
Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
Phase 2
Recruiting
- Conditions
- Sever Aplastic AnaemiaElderly (People Aged 65 or More)Immunosuppressive Treatment
- Interventions
- Drug: Dose-attenuated IST and Hetrombopag
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-06-08
- Target Recruit Count
- 65
- Registration Number
- NCT07010237
- Locations
- 🇨🇳
Red Blood Cell Diseases Center, Tianjin, Tianjin, China
The Mutation Profile and Prognosis in AML With IDH1/2 Mutation
Completed
- Conditions
- AML
- First Posted Date
- 2025-06-04
- Last Posted Date
- 2025-06-04
- Target Recruit Count
- 1015
- Registration Number
- NCT07004816
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
Phase 2
Recruiting
- Conditions
- Relapsed or Refractory Aggressive B-cell Lymphoma
- Interventions
- Drug: Chimeric Antigen Receptor T Cells (CAR-T)
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-06-17
- Target Recruit Count
- 25
- Registration Number
- NCT06996132
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry
Not yet recruiting
- Conditions
- Hemophilia
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-05-28
- Target Recruit Count
- 100
- Registration Number
- NCT06992076
Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage
Not Applicable
Not yet recruiting
- Conditions
- Adult ALLMPAL
- Interventions
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-05-28
- Target Recruit Count
- 50
- Registration Number
- NCT06991920
Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial
Phase 2
Recruiting
- Conditions
- Primary Immune Thrombocytopenia (ITP)
- Interventions
- Drug: Romiplostim N01 combined with dexamethasone
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-05-28
- Target Recruit Count
- 129
- Registration Number
- NCT06992128
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China
A Study of CT0596 in Plasma Cell Leukemia
Early Phase 1
Not yet recruiting
- Conditions
- Plasma Cell Leukemia
- Interventions
- Drug: CAR-T cells Infusion chimeric antigen receptor T cells
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-05-23
- Target Recruit Count
- 27
- Registration Number
- NCT06988059
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, Tianjin, China